Castration-Refractory Prostate Cancer: New Drugs in the Pipeline

被引：13
作者：
Schrijvers, Dirk [1 ]
Van Erps, Peter [2 ]
Cortvriend, Jim [2 ]
机构：
[1] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Hematooncol, B-2020 Antwerp, Belgium
[2] Ziekenhuisnetwerk Antwerpen Middelheim, Dept Urol, B-2020 Antwerp, Belgium
来源：
ADVANCES IN THERAPY | 2010年 / 27卷 / 05期
关键词：
castration-refractory prostate cancer; docetaxel; cabazitaxel; abiraterone acetate; angiogenesis modulators; vaccines; PHASE-II TRIAL; ABIRATERONE ACETATE; 2ND-LINE CHEMOTHERAPY; PLUS PREDNISONE; CLINICAL-TRIAL; DOCETAXEL; INHIBITOR; CYP17; MITOXANTRONE; THALIDOMIDE;
D O I：
10.1007/s12325-010-0038-1
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naive or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
引用
收藏
页码：285 / 296
页数：12
相关论文
共 50 条
  • [41] Management of Castration-Resistant, Taxane-Resistant Prostate Cancer
    Beer, Tomasz M.
    ONCOLOGY-NEW YORK, 2017, 31 (08): : 633 - 636
  • [42] The National Registry of treatment regimens in patients with metastatic castration-resistant prostate cancer in the Russian Federation
    Karyakin, O. B.
    Kaprin, A. D.
    Ivanov, S. A.
    ONKOUROLOGIYA, 2019, 15 (03): : 78 - 88
  • [43] New Therapeutic Strategies for Castration-Resistant Prostate Cancer
    Tanaka, Tomoaki
    Nakatani, Tatsuya
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (03) : 373 - 383
  • [44] New Treatment Options in Castration-Resistant Prostate Cancer
    Armstrong, Andrew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (5.5): : 690 - 693
  • [45] The Effect of Time to Castration Resistance on Overall Survival and Success of Docetaxel Treatment in Castration Resistant Prostate Cancer Patients
    Suer, Evren
    Hamidi, Nurullah
    Akpinar, Cagri
    Gokce, Mehmet Ilker
    Gulpinar, Omer
    Turkolmez, Kadir
    Beduk, Yasar
    Baltaci, Sumer
    UROLOGY JOURNAL, 2019, 16 (05) : 453 - 457
  • [46] The atypical site of ureteral metastasis in a patient with castration-refractory prostate cancer. A clinical case and a review of literature
    Alekseev, B. Ya.
    Ivyushko, K. M.
    Kalpinsky, A. S.
    Vorobyev, N. V.
    Golovashchenko, M. P.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2014, 10 (01): : 82 - 87
  • [47] Management of advanced prostate cancer - new drugs
    Ullen, Anders
    Shah, Carl-Henrik
    Kirkali, Ziya
    ACTA ONCOLOGICA, 2011, 50 : 137 - 140
  • [48] How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer
    Dreicer, Robert
    CANADIAN JOURNAL OF UROLOGY, 2014, 21 : 93 - 97
  • [49] Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer
    Al-Mansouri, Loma
    Gurney, Howard
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 (06) : 288 - 295
  • [50] Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer
    Malik, Zafar
    Payne, Heather
    Ansari, Jawaher
    Chowdhury, Simon
    Butt, Mohammad
    Birtle, Alison
    Sundar, Santhanam
    Eswar, Chinnamani Vee
    Hughes, Simon
    Bahl, Amit
    ADVANCES IN THERAPY, 2013, 30 (12) : 1041 - 1066
12345